The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future.

AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair

In this round table discussion chaired by Gert Ossenkoppele, Amsterdam University Medical Center, our experts, Charles Craddock, Jacquline Cloos, Adriano Venditti, and Christian Thiede answer questions from the audience and discuss the use of MRD as a surrogate for overall survival and the need for retrospective trials in this area. They also discuss the effectiveness of MRD in a maintenance setting, leukemic stem cells as a marker for MRD, and pivotal clinical trials in the field, some of which are ongoing.